LNSR earnings

7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base Climbs to 440 Systems, Driven by 39% Growth in ALLY Placements ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2026 and provided an update on key operational initiatives. "Our first quarter total revenue and related system placement results decre

ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. LENSAR's management will host a conference call and webcast at 8:30 am ET on Friday, May 8, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives. To participate by telephone, please use this registration link. All participants must use the link to complete the online registra

15 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over December 31, 2024 Recurring revenue exceeded $46.3 million for the full year; increased 15% over 2024 ORLANDO, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on key operational initiatives. "Wh

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC ("Alcon") to terminate the merger agreement between the parties. We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unli

18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

         14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results and recent corporate highlights. To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance

         24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring revenue growth in twelve-month trailing average Worldwide procedure volumes increased 29% over third quarter of 2023 Installed system base grew 20% over third quarter of 2023 ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307 1963 (International). The conference ID is 8444582. To access the live webcast, please go t

17 New ALLY® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval granted for commercial distribution of ALLY; First EU and Southeast Asia systems shipped Continued robust worldwide procedure growth; 2Q 2024 procedure volumes increased 19% over 2Q 2023 Installed system base grew 16% over 2Q 2023 LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2024 and provided an update on key

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the Company's second quarter 2024 financial results will be released before market open on Thursday, August 8, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, August 8, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 274 8461 (Domestic) or (203) 518 9848 (International). The conference ID is LENSAR. To access the live webcast, please go to the Investors section of LENSAR's website at www.lensar.com

Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY® Adaptive Cataract Treatment System installed base to 65 systems LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives. "Recognition of ALLY's advantages, its ability to achieve higher efficiencies for surgeons and staff as well as better surgical outcomes for patients, allowed us to deliver continued 20%+ revenue growth in the first quart

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 267 6316 (Domestic) or (203) 518 9783 (International). The conference ID is LENSAR. To access the live webcast, please go to the Investors section of LENSAR's website at www.lensa

44 ALLY® Adaptive Cataract Treatment Systems were placed in 2023, significantly exceeding the target of 30, increasing the ALLY installed base to 54 and a backlog of 9 additional systems as of December 31, 2023 Total revenue increased 18% in the fourth quarter and 19% over full year 2022 LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2023 and provided an update on key operational initiatives. "Our strong performance throughout 2023 continued in the fourth quarter, resulting in tot

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2023 financial results will be released before market open on Monday, March 4, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Monday, March 4, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (888) 259 6580 (Domestic) or (206) 962 3782 (International). The conference ID number is 48034263. To access the live webcast, please go to the Investors section of LENSA

Increased ALLY® Adaptive Cataract Treatment System installed base to 39 systems with a backlog of 8 additional systems for installation as of September 30, 2023 Total revenue increased 26% and U.S. procedure volume increased 16% over the third quarter 2022 LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2023 and provided an update on key operational initiatives. "We have seen continued strength in our business in the third quarter, with total revenue up 26% and U.S. procedure volume increasing

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2023 financial results will be released before market open on Thursday, November 9, 2023. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 9, 2023 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (888) 660 5501 (Domestic) or (646) 960 0416 (International). The conference ID number is 7303394. To access the live webcast, please go to the Investors section of LENSAR's we

Increased ALLY® Adaptive Cataract Treatment System installed base to 28 systems with a backlog of 6 additional systems for installation as of June 30, 2023 U.S. procedure volumes increased 13% over second quarter 2022; 1H 2023 procedure volumes increased 15% year-over-year at sites that have upgraded from LENSAR Laser System (LLS) or added an ALLY $25.5 million cash available to support ongoing ALLY commercial launch activities and market expansion initiatives LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's second quarter 2023 financial results will be released before market open on Wednesday, August 9, 2023. LENSAR's management will host a conference call and webcast at 8:30 am ET on Wednesday, August 9, 2023 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (888) 259 6580 (Domestic) or (416) 764 8624 (International). The conference ID number is 93649834. To access the live webcast, please go to the Investors section of LE

Increased ALLY® Adaptive Cataract Treatment System installed base to 19 systems with a backlog of additional 13 systems as of May 12, 2023 U.S. procedure volumes increased 13% over first quarter 2022; Procedure volumes increased >20% year-over-year at sites that have upgraded from LENSAR Laser System (LLS) to ALLY Significantly strengthened balance sheet through $20 million private placement LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2023 and provided an update on key operational init

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's first quarter 2023 financial results will be released before market open on Monday, May 15, 2023. LENSAR's management will host a conference call and webcast at 8:30 am ET on Monday, May 15, 2023 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (888) 396 8049 (Domestic) or (416) 764 8646 (International). The conference ID number is 32566197. To access the live webcast, please go to the Investors section of LENSAR's webs

Installed ten ALLY® Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023 Positive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALLY LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives. "The reception to our next generation ALLY System supports our confidence in this new techn

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2022 financial results will be released before market open on Thursday, March 16, 2023. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, March 16, 2023 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (888) 886 7786 (Domestic) or 416 764 8658 (International). The conference ID number is 94867603. To access the live webcast, please go to the Investors sect

Company Launches ALLY™ Adaptive Cataract Treatment System Third Quarter U.S. Procedure Volume Increases 9% over Q3 2021 LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2022 and provided a business update. "The third quarter was highlighted by the successful U.S. launch of the ALLY System during the week of August 15th, a pivotal corporate milestone, and the next important step in continuing the transition to our next generation system. We have installed multiple ALLY Systems in select sit

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022. LENSAR's management will host a conference call and webcast at 8:30 am ET on Wednesday, November 9, 2022 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (888) 396 8049 (Domestic) or 416 764 8646 (International). The conference ID number is 51285282. To access the live webcast, please go to the Investors section of LE

Company Receives FDA Clearance of ALLY™ Adaptive Cataract Treatment System Second Quarter Procedure Volume Increases 8%, in the Aggregate, and 15% in the U.S. Over Q2 2021 Levels LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives. "In June, we achieved a significant milestone in LENSAR's history, the Food and Drug Administration ("FDA")'s clearance of our ALLY Adaptive Cataract Treatment System. Interest in the ALLY System has been high since

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's second quarter 2022 financial results will be released before market open on Monday, August 8, 2022. LENSAR's management will host a conference call and webcast at 8:30 am ET on Monday, August 8, 2022 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (888) 396-8049 (Domestic) or (416) 764-8646 (International). The conference ID number is 64265948. To access the live webcast, please go to the Investors section of LENSAR's

First Quarter Revenue Increases 33% Over 2021 Levels First Quarter Procedure Volume Increases 38% Over 2021 Levels LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2022 and provided an update on operational initiatives. "We have started 2022 on an impressive note by achieving more than 30% growth in both revenue and worldwide procedure volumes as compared to the first quarter of last year," said Nick Curtis, Chief Executive Officer of LENSAR. "In addition, we took the first step forward in bri

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's first quarter 2022 financial results will be released before market open on Monday, May 9, 2022. LENSAR's management will host a conference call and webcast at 8:30 am ET on Monday, May 9, 2022 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (833) 312-1363 (Domestic) or (236) 712-2498 (International). The conference ID number is 3354968. To access the live webcast, please go to the Investors section of LENSAR's website

2021 Revenue Increases $8.1 million or 31% over 2020 Levels Procedure Volume Increases over 2020 Levels by 37% in Fourth Quarter and by 35% in 2021 Cash and Cash Equivalents of $31.6 Million Reflect Cash Utilization of $0.7 Million in the Fourth Quarter LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2021 and provided an update on key strategic and operational initiatives. "2021 was a year of progress for LENSAR. Revenue and procedure volume in 2021 returned to our historical

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the U.S. Food and Drug Administration ("FDA") has accepted its 510(k) submission for its next-generation ALLY™ Adaptive Cataract Treatment System for substantive review. The submission seeks marketing clearance for the ALLY Adaptive Cataract Treatment System and is the first stage of a planned, two step commercial release strategy. As part of this strategy, the Company plans to submit an additional 510(k) application seeking clearance for the phacoemulsification features within the integrated

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2021 financial results will be released before market open on Thursday, March 3, 2022. LENSAR's management will host a conference call and webcast at 8:30am ET on Thursday, March 3, 2022 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (833) 312-1363 (Domestic) or (236) 712-2498 (International). The conference ID number is 7098914. To access the live webcast, please go to the Investors sectio

Third Quarter 2021 Procedure Volumes Increase 23% over 2020 Levels Cash and Cash Equivalents of $32.3 Million reflect Cash Utilization of $2.2 Million in the Quarter LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2021 and provided an update on key strategic and operational initiatives. "The third quarter was one of continued progress on both the commercial and research and development aspects of our business. Our commercial operations have continued to rebound from the pandemic-related s

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's third quarter 2021 financial results will be released before market open on Monday, November 8, 2021. LENSAR's management will host a conference call and webcast at 8:30am ET on Monday, November 8, 2021 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (833) 312-1363 (Domestic) or (236) 712-2498 (International). The conference ID number is 5587659. To access the live webcast, please go to the Investor Relations section of

Second Quarter and First Half 2021 Procedure Volumes Increase 70% and 42% over 2020 Levels Cash and Cash Equivalents of $34.6 Million reflects Cash Utilization of $1.3 Million in the Second Quarter LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2021 and provided an update on key strategic and operational initiatives. "We have made significant progress across a number of fronts. Our commercial operations have rebounded from the COVID-19 pandemic, and we have returned to growing the business as